论文部分内容阅读
目的:采用网状n meta分析方法系统评价胰升糖素样肽1受体激动剂(GLP-1RA)、二甲双胍联合噻唑烷二酮类药物、α-糖苷酶抑制剂、肌醇治疗多囊卵巢综合征(PCOS)患者的临床疗效。n 方法:根据人群、干预措施、比较、结果和研究设计(PICOS)标准原则制定检索策略，计算机检索PubMed、EMBase、Cochrane Library、万方数据及CNKI数据库，检索时限从建库至2020年11月。由2名研究者严格按照纳入排除标准独立筛选随机对照试验，提取纳入文献的基本信息和结局指标，并采用Corchrane偏倚风险评估工具对文献进行方法学质量评价。使用软件STATA 14.0和R语言对各效应指标进行网状n meta分析。不具有量纲差异的连续性变量采用加权平均差及95%n CI计算，具有量纲差异的连续性变量采用标准化均数差及95%n CI计算。n 结果:本研究共纳入27项研究进行分析，合计1 445例患者。网状n meta分析显示，阿卡波糖在降低血总睾酮的方面较之于其余药物显示出较好的疗效[累积概率排序曲线图(SUCRA)为89.4%]，GLP-1RA的疗效在降低体重指数及稳态模型评估的胰岛素抵抗指数(HOMA-IR)方面疗效最好(SUCRA分别为99.1%、89.2%)，而肌醇在降低血清空腹胰岛素、HOMA-IR、血总胆固醇及血三酰甘油方面可能有着较优的疗效(SUCRA分别为94.5%、85.4%、96.6%、82.8%)。n 结论:阿卡波糖在降低血总睾酮方面较之其他药物可能具有优势。GLP-1RA更有助于改善PCOS患者的体重指数及HOMA-IR。肌醇作为一种胰岛素增敏剂在降低血清空腹胰岛素、HOMA-IR、血总胆固醇及血三酰甘油方面都有较好疗效，并且目前的研究中暂未有不良反应发生的报道，值得进一步临床研究证实。“,”Objective:The study was designed to evaluate the efficacy in polycystic ovary syndrome (PCOS) of glucagon-like peptide-1 receptor agonists (GLP-1RA), metformin combined with thiazolidinediones, α-glucosidase inhibitor, and inositol.Methods:Eligible studies were searched in databases of PubMed, EMBase, Cochrane Library, Wanfang data, and CNKI based on population, interventions, comparisons, outcomes, and study design (PICOS) principle (inception to Nov 2020). Two researchers independently screened randomized controlled trials in strict accordance with the inclusion and exclusion criteria, extracted basic information and outcomes of included studies, and used Cochrane risk of bias tool to evaluate the methodological quality of the literature. Network meta-analysis was conducted by STATA 14.0. Continuous variables without dimensional differences were calculated by weighted mean difference and 95%n CI, and continuous variables with dimensional differences were calculated using standardized mean difference and 95%n CI.n Results:A total of 27 studies with 1 445 patients were included in this study. Network meta-analysis showed that acarbose presented a better efficacy than other interventions in reducing total testosterone [surface under the cumulative ranking curve (SUCRA): 89.4%]. GLP-1RAs may have the best efficacy in reducing body mass index and homeostasis model assessment for insulin resistance (HOMA-IR; SUCRA: 99.1%, 89.2%, respectively), while using inositol may be a good choice to reduce serum fasting insulin, HOMA-IR, blood total cholesterol, and blood triglycerides (SUCRA: 94.5%, 85.4%, 96.6%, and 82.8%, respectively).Conclusions:Acarbose may have advantages over other antihyperglycemic drugs in lowering blood testosterone. GLP-1RAs are more helpful to improve body mass index and HOMA-IR in PCOS patients. Inositol, as an insulin sensitizer, has a favorable effect on reducing fasting insulin, HOMA-IR, blood total cholesterol, and blood triglycerides, and there are no reports of side effects in current researches. Further study is still needed to confirm its efficacy.